Tyk2

Tyrosine kinase 2 (TYK2) is a non-receptor Janus kinase (JAK) family member essential for cytokine signaling in immune cells^[1][2]. Mechanistically, TYK2 mediates signal transduction downstream of interleukin-12 (IL-12), interleukin-23 (IL-23), type I interferons (IFN-α/β), and the IL-10 cytokine family, activating STAT transcription factors and regulating T helper cell differentiation^[1][2][3]. Compared with other JAK isoforms, TYK2 exhibits distinct pseudokinase (JH2) and kinase (JH1) domains, enabling selective allosteric modulation without broadly inhibiting JAK1-3^[4][2]. Loss-of-function or kinase-inactive mutations in TYK2 lead to impaired IFN and IL-12 signaling, resulting in immune deficiencies and altered antiviral responses in murine and human models^[5][6]. In disease contexts, TYK2 is implicated in autoimmune disorders, including psoriasis, inflammatory bowel disease, and systemic lupus erythematosus, via dysregulated IL-23/TH17 and type I interferon pathways^[7][8][2][3]. Selective inhibitors targeting the TYK2 JH2 pseudokinase domain, such as deucravacitinib or TAK-279, suppress pathogenic cytokine signaling with high specificity, preserving other JAK-mediated functions and providing therapeutic benefits in preclinical and clinical studies^[4][7][2][3]. Experimental applications exploit TYK2-selective inhibition to dissect cytokine-driven immune responses and validate downstream transcriptional and phenotypic effects in immune cell models^[9][3]. These compounds demonstrate potent modulation of human T cells, primary immune cells, and murine models of colitis or psoriasis, highlighting their translational relevance^[4][7][2].